The Efficacy Of Low-dose Flupentixol Melitracen In Treating The Patients With Functional Dyspepsia

OBJECTIVE: To observe the clinical efficacy of low-dose antidepressant Flupentixol andMelitracen Tablets (Brand names: Deaxit) on the patients with functional dyspepsia (FD).METHODS: This was a random, control, single-center, open, and prospective study. TheFD patients fulfilled the Roman Ⅲcriteria were randomly divided into study group (group S) andcontrol group (group C). The patients in group C were treated with rabeprazole10mg1times/d,mosapride5mg3times/d; while in group S with rabeprazole10mg1times/d, mosapride5mg3times/d, and Deanxit1piece/d before breakfast. The treatment course was8weeks, and another4weeks for follow-up observation. The Functional dyspepsia Rating Scale(FDRS), Self-RatingAnxiety Scale(SAS) and Self-Rating Depression Scale(SDS) were provide to evaluate theefficacy of these treatments.RESULTS: Eighty-one cases in group S and80cases in group C had respectively completed thetreatment. The difference of age, sex, FDRS score, SAS score,SDS score in the two groups wasnot statistical at the baseline (W0)(p>0.05). At the8thweek (W8), the SAS and SDS scoredecreased significantly compared with baseline (W0) in the patients with mild to moderatedepression in the both groups (p<0.001). However, the SAS and SDS scores had not a significantdecline in the patients with non-depression or with obvious anxiety (p>0.05,respectively).The total efficacy (93.15%) for patients with mild to moderate depression in group S washigher than that in group C (81.15%, p=0.028). However, the total efficacy for the patients withobvious depression was not significantly different between the two groups (p=0.061).After treatment, FDRS score declined gradually (W0:10.31±2.20；W4：5.04±2.38；W8：3.22±2.20；p<0.001) in the patients with moderate to obvious depression in group S, but it didn’tchange much in group C (p>0.05). The percentage reduction of SAS score and SDS score inpatients with non-depression and obvious depression didn’t have a significant difference betweengroup S and group C(p>0.05). However, the percentage reduction of FDRS score in group S isobviously higher than in group C (p=0.001). The percentage reductions of FDRS score, SDS score,and SAS score in patients with mild to moderate depression were lower in group S than those ingroup C respectively(p=0.000). There was no more reduction in FDRS score in the4-weekfollow-up observation in the both groups.CONCLUSIONS: Low dose Flupentixol and Melitracen Tablets(Deaxit) can effectivelyalleviate the clinical symptoms in all FD patients, and improve the psychology evaluation inpatients with mild to moderate depression. The, effect of this agent on the FD symptoms may notdepend on its anti-depression function only.